Last reviewed · How we verify
Hydergine (ERGOLOID MESYLATES)
Hydergine (Ergoloid Mesylates) is a small molecule medication originally developed by Novartis and currently owned by the same company. It was first approved by the FDA in 1953 for the treatment of dementia. Despite being off-patent, there are still 11 generic manufacturers available. Key safety considerations include its bioavailability of 25%. Hydergine's commercial status is generic, with no active Orange Book patents.
At a glance
| Generic name | ERGOLOID MESYLATES |
|---|---|
| Sponsor | Novartis |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Dementia
Common side effects
- Nausea
- Gastric disturbances
Key clinical trials
- ERG/5-HTP in Fragile X Syndrome (FXS) (PHASE2)
- Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydergine CI brief — competitive landscape report
- Hydergine updates RSS · CI watch RSS
- Novartis portfolio CI